Conference name
Exhibitors & Sponsors




Matthias Christgen

Molecular markers in breast cancer:  Research and diagnostic testing, with special reference to HER2, MDR1 and Ki67

Handout (pdf 61p)

Handout (pdf 15p)


Therapeutic decision making in breast cancer depends on histopathological biomarkers. This concept has been developed in the 1970ies, when anti-hormone therapy became a cornerstone in the clinical managment of ER-positive breast cancer. Gene expression profiling studies performed in the 1990ies and in the last decade have further improved our understanding of breast cancer as a heterogeneous disease requiring tailored therapeutic approaches. Current research in the field of molecular profiling and next generation sequencing offers a plethora of potential new markers for clinical application. Reliable routine diagnostic assessment of such markers and the establishment of a framework for inter‑laboratory standardization and quality control are of major importance for health care. This is  exemplified by three markers with very different significance in clinical diagnostics, namely Ki67, MDR1 and HER2. With respect to HER2, the ASCO/CAP 2013 guidelines will be discussed in detail.


Dr. Matthias Christgen is a reference histopathologist for clinical trials on breast cancer at the Institute of Pathology of the Hannover Medical School, Germany. He studied Medicine at the Universites of Halle‑Wittenberg (1998-2000) and Kiel (2000-2003), Germany, and was awarded DAAD and SDV scholarships for training in molcular oncology at the Case Western Reserve University, Cleveland Ohio (2003‑2004). Dr. Matthias Christgen received his MD on an experimental pancreatic cancer model in 2005. He completed the MD/PhD program at the Hannover Biomedical Research School, Germany (2005-2008) and received his PhD for experimental studies on human breast cancer stem cell phenotypes (2008). In 2009 he joined training in surgical pathology at the Institute of Pathology of the Hannover Medical School, Germany. He was awarded a Hannelore-Munke Fellowship for studies on the molecular pathology of human lobular breast cancer (2011). Dr. Matthias Christgen was granted the venia legendi in 2013.       


Exhibitors & Sponsors